3 Garment Exporter, Specialty Pharma Company and Fluorospecialty Chemicals and Packaging Films Group Stocks With a Strong Future Roadmap: Pearl Global Industries, Ajanta Pharma and SRF
- November 2, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Pearl Global Industries, Ajanta Pharma and SRF: ROE of 14.9% to 23.3% and FY22 to FY26 revenue CAGR of 6.1% to 16.5%. Prices as of 30 Oct 2026.
Quick Answer
The three garment, specialty pharma and fluoro stocks to watch are Pearl Global Industries, Ajanta Pharma and SRF. Their return on equity ranges from 14.9% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 16.5%. Ajanta Pharma has the highest return on equity at 23.3%, while Pearl Global Industries has the fastest revenue growth at 16.5% a year. Prices are based on the 30 October 2026 close, and this article is educational, not investment advice.
Garment, specialty pharma and fluoro stocks offer a focused view of a sector where demand keeps widening. Pearl Global Industries, Ajanta Pharma and SRF cover a garment exporter, a specialty pharma company and a fluorospecialty chemicals and packaging films group.
This list covers three garment, specialty pharma and fluoro stocks with complete current figures: Pearl Global Industries, Ajanta Pharma and SRF. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Garment, Specialty Pharma and Fluoro Stocks?
Garment, specialty pharma and fluoro stocks are listed companies that make garments for leading international brands, sell specialty branded generics in India and emerging markets, and produce fluorospecialty chemicals, refrigerant gases and packaging films. Their earnings depend on export orders, prescriptions and input costs.
Garment, Specialty Pharma and Fluoro Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Pearl Global Industries | 1,192.6 | 11,806 | 38.9 | 35.2 | 19.0 | 0.65 |
| Ajanta Pharma | 3,508.8 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| SRF | 2,335.5 | 69,274 | 30.4 | 33.9 | 14.9 | 0.35 |
On valuation, SRF trades at a P/E below the industry P/E, while Pearl Global Industries and Ajanta Pharma trade above it, which reflects the growth the market already expects. Readers comparing garment, specialty pharma and fluoro stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Garment, Specialty Pharma and Fluoro Stocks Have a Strong Roadmap in India?
Garment, specialty pharma and fluoro stocks have a strong roadmap in India because global brands diversifying sourcing, steady specialty medicine demand and wider use of specialty chemistry keep widening the market for these export focused companies.
- Sourcing shift. Global brands add Indian factories.
- Specialty care. Focused medicines support steady earnings.
- Specialty chemistry. Fluorochemicals serve many end uses.
Why Pearl Global Industries Features Among These Garment, Specialty Pharma and Fluoro Stocks
Among the garment, specialty pharma and fluoro stocks on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.
Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.
Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What to watch: Watch order inflow from global brands and the ramp-up of newer factories.
Why Ajanta Pharma Features Among These Garment, Specialty Pharma and Fluoro Stocks
Among the export oriented shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.
Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.
Why SRF Features Among These Garment, Specialty Pharma and Fluoro Stocks
Among the three companies on this list, SRF is a diversified chemicals and materials company with fluorospecialty chemicals, refrigerant gases, packaging films and technical textiles, with customers in India and overseas.
The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9.
Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%.
Roadmap: The company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.
What to watch: Track specialty chemicals growth, refrigerant gas demand and capacity additions.
Pearl Global Industries vs Ajanta Pharma vs SRF on Key Financials
The table below sets the three garment, specialty pharma and fluoro stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Pearl Global Industries | 2,747 | 5,062 | 16.5% | 270 | 5.3% |
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| SRF | 12,549 | 15,894 | 6.1% | 1,835 | 11.5% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. SRF has the largest FY26 revenue at Rs 15,894 crore, and Pearl Global Industries shows the fastest revenue growth with a 16.5% compound annual rate. A useful habit with garment, specialty pharma and fluoro stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Garment, Specialty Pharma and Fluoro Stocks
Every theme carries risks that deserve a check before any decision. For these garment, specialty pharma and fluoro stocks, the main points are: Long-term export oriented shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter garment, specialty pharma and fluoro stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Garment, Specialty Pharma and Fluoro Stocks
Garment, specialty pharma and fluoro stocks reward patient research into demand, execution and financial strength. Pearl Global Industries, Ajanta Pharma and SRF each have a clear plan to grow. Based on the 30 October 2026 close, Pearl Global Industries trades at Rs 1,192.6, Ajanta Pharma at Rs 3,508.8 and SRF at Rs 2,335.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these garment, specialty pharma and fluoro stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track garment, specialty pharma and fluoro stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are garment, specialty pharma and fluoro stocks?
Ans. Garment, specialty pharma and fluoro stocks are listed companies that make garments for leading international brands, sell specialty branded generics in India and emerging markets, and produce fluorospecialty chemicals, refrigerant gases and packaging films. Their earnings depend on export orders, prescriptions and input costs. This list looks at three of them, Pearl Global Industries, Ajanta Pharma and SRF, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.
Which garment, specialty pharma and fluoro stocks are covered in this list?
Ans. This list covers Pearl Global Industries, Ajanta Pharma and SRF. Based on the 30 October 2026 close, Pearl Global Industries traded at Rs 1,192.6, Ajanta Pharma at Rs 3,508.8 and SRF at Rs 2,335.5. Their return on equity ranges from 14.9% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 16.5%.
Why do garment, specialty pharma and fluoro stocks have a strong future roadmap in India?
Ans. Garment, specialty pharma and fluoro stocks have a strong roadmap in India because global brands diversifying sourcing, steady specialty medicine demand and wider use of specialty chemistry keep widening the market for these export focused companies. The main drivers are as follows. Sourcing shift. Global brands add Indian factories. Specialty care. Focused medicines support steady earnings. Specialty chemistry. Fluorochemicals serve many end uses. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Pearl Global Industries performed financially?
Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has SRF performed financially?
Ans. Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%. The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9. Looking ahead, the company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.
What risks should investors check before buying garment, specialty pharma and fluoro stocks?
Ans. Investors should check a few risks before buying garment, specialty pharma and fluoro stocks. Currency moves. Export earnings move with the rupee. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of garment, specialty pharma and fluoro stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.